ABSTRACT
This letter describes the discovery and SAR optimization of tetrazoyl tetrahydroquinoline derivatives as potent CETP inhibitors. Compound 6m exhibited robust HDL-c increase in hCETP/hApoA1 double transgenic model and favorable pharmacokinetic properties.
Subject(s)
Cholesterol Ester Transfer Proteins/antagonists & inhibitors , Drug Design , Hypolipidemic Agents/chemical synthesis , Quinolines/chemistry , Tetrazoles/chemical synthesis , Animals , Apolipoprotein A-I/genetics , Apolipoprotein A-I/metabolism , Cholesterol Ester Transfer Proteins/genetics , Cholesterol Ester Transfer Proteins/metabolism , Cholesterol, HDL/drug effects , Cholesterol, HDL/metabolism , Dogs , Female , Hypolipidemic Agents/chemistry , Hypolipidemic Agents/pharmacokinetics , Injections, Intravenous , Male , Mice , Mice, Transgenic , Quinolines/chemical synthesis , Quinolines/pharmacokinetics , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship , Tetrazoles/chemistry , Tetrazoles/pharmacokineticsABSTRACT
This Letter describes the discovery and SAR optimization of 1,5-tetrahydronaphthyridines, a new class of potent CETP inhibitors. The effort led to the identification of 21b and 21d with in vitro human plasma CETP inhibitory activity in the nanomolar range (IC(50)=23 and 22nM, respectively). Both 21b and 21d exhibited robust HDL-c increase in hCETP/hApoA1 dual heterozygous mice model.
Subject(s)
Cholesterol Ester Transfer Proteins/antagonists & inhibitors , Naphthyridines/pharmacology , Animals , Cholesterol, HDL , Dose-Response Relationship, Drug , Drug Design , Humans , Inhibitory Concentration 50 , Mice , Naphthyridines/chemical synthesis , Structure-Activity RelationshipABSTRACT
Cholesteryl ester transfer protein (CETP) catalyses the exchange of cholesteryl ester and triglyceride between HDL and apoB containing lipoprotein particles. The role of CETP in modulating plasma HDL cholesterol levels in humans is well established and there have been significant efforts to develop CETP inhibitors to increase HDL cholesterol for the treatment of coronary artery disease. These efforts, however, have been hampered by the fact that most CETP inhibitors either have low potency or have undesirable side effects. In this study, we describe a novel benzazepine compound evacetrapib (LY2484595), which is a potent and selective inhibitor of CETP both in vitro and in vivo. Evacetrapib inhibited human recombinant CETP protein (5.5 nM IC(50)) and CETP activity in human plasma (36 nM IC(50)) in vitro. In double transgenic mice expressing human CETP and apoAI, evacetrapib exhibited an ex vivo CETP inhibition ED(50) of less than 5 mg/kg at 8 h post oral dose and significantly elevated HDL cholesterol. Importantly, no blood pressure elevation was observed in rats dosed with evacetrapib at high exposure multiples compared with the positive control, torcetrapib. In addition, in a human adrenal cortical carcinoma cell line (H295R cells), evacetrapib did not induce aldosterone or cortisol biosynthesis whereas torcetrapib dramatically induced aldosterone and cortisol biosynthesis. Our data indicate that evacetrapib is a potent and selective CETP inhibitor without torcetrapib-like off-target liabilities. Evacetrapib is currently in phase II clinical development.
Subject(s)
Benzodiazepines/adverse effects , Benzodiazepines/pharmacology , Cholesterol Ester Transfer Proteins/antagonists & inhibitors , Cholesterol Ester Transfer Proteins/metabolism , Cholesterol, HDL/blood , Aldosterone/metabolism , Animals , Blood Pressure/drug effects , Cell Line, Tumor , Humans , Male , Mice , Mice, Inbred NOD , Rats , Substrate SpecificityABSTRACT
In guinea pigs, we found that intravenous 5,8,11,14-eicosatetraenamide (N-2-hydroxyethyl), arachidonylethanolamide (anandamide), 0.3-10.0 mg/kg, did not inhibit leukotriene D(4) (LTD(4))-induced airway obstruction, while inhaled anandamide, 21.8 and 43.6 microg/kg (estimated inhaled doses), significantly reduced this airway obstructive effect by 24.8+/-8.8 and 42.0+/-11.2%, respectively. In contrast, aerosolized anandamide (43.6 microg/kg) was ineffective against histamine-induced bronchoconstriction. Thus, inhaled, but not intravenous anandamide selectively antagonizes the bronchospasm produced by LTD(4).